NCT06949423 Assessing the Impact of dTMS on Neural Targets Associated With Alcohol Use Disorder
| NCT ID | NCT06949423 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Stanford University |
| Condition | Alcohol Use Disorder (AUD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-12-17 |
| Primary Completion | 2030-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2025-12-17 with a primary completion date of 2030-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the efficacy of deep transcranial magnetic stimulation as a treatment for Veterans with Alcohol Use Disorder (AUD) to decrease the exceedingly high rate of relapse associated with this condition.
Eligibility Criteria
Inclusion Criteria: * Age 18-75. * Current DSM-5 diagnosis of moderate to severe AUD (\≥4 diagnostic symptoms). * Ability to obtain a Motor Threshold (MT) will be determined during the screening process. * Has an adequately stable condition and environment to enable attendance at scheduled clinic visits. * Able to read, understand and voluntarily sign the Informed Consent Form prior to participating in any study-specific procedures or assessments. * If on a medication regimen for comorbid symptoms, that regimen will be stable for the duration of the study and patient will be willing to remain on this regimen during the treatment phase. * Fluency in English. Exclusion Criteria: * Transcranial magnetic stimulation (TMS) and magnetic resonance imaging (MRI) contraindications: such as a cardiac pacemaker, cochlear implant, or an implanted device (deep brain stimulation, metal in the head, metal in the body, claustrophobia, pregnant or breastfeeding or other ferromagnetic device/objected in the head and body within 30 cm of the treatment coil. * General medical condition, disease or neurological disorder that interferes with the assessments or participation. * Unable to safely withdraw, at least two weeks prior to treatment, from medications that increase seizure risk. * Current substance abuse (except caffeine or nicotine) as determined by positive toxicology screen. * Have a mass lesion, cerebral infarct, or other active CNS disease, including an alcohol-related seizure or a seizure disorder. * A recent suicide attempt (defined as within the last 30 days) or presence of current suicidal plan or intent. Patients at risk for suicide will be required to establish a written safety plan involving their primary therapist before entering the study. * Severe impediment to vision, hearing and/or hand movement, likely to interfere with the ability to follow study protocols. * Greater than mild traumatic brain injury (defined as greater than 10 minutes loss of consciousness). * Taking benzodiazepine or neuroleptic medications, or any medication known to alter seizure threshold * Acute or unstable chronic illness. * Current or lifetime history of bipolar disorder or psychosis
Contact & Investigator
Claudia B Padula, PhD
PRINCIPAL INVESTIGATOR
Stanford University
Frequently Asked Questions
Who can join the NCT06949423 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Alcohol Use Disorder (AUD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06949423 currently recruiting?
Yes, NCT06949423 is actively recruiting participants. Contact the research team at samward@stanford.edu for enrollment information.
Where is the NCT06949423 trial being conducted?
This trial is being conducted at Palo Alto, United States.
Who is sponsoring the NCT06949423 clinical trial?
NCT06949423 is sponsored by Stanford University. The principal investigator is Claudia B Padula, PhD at Stanford University. The trial plans to enroll 100 participants.